Literature DB >> 26246111

[Follow-up of urological tumor treatment].

C-H Ohlmann1, P Albers, K Boehm, M Graefen, O W Hakenberg, M Kuczyk, J Graf, I Peters, C Protzel.   

Abstract

Follow-up of patients after curative treatment of urological cancer is an important component of the treatment of patients. The aim of the follow-up is to monitor the success of treatment and to identify local or distant recurrences early to be able to initiate further treatment. Investigations used for the monitoring should follow the principle "as much as necessary, as little as possible". The interval and method of follow-up investigations should be based on the risk of recurrence for the individual patient. In recent years follow-up schemes have been improved and, for example in testicular cancer, have been adjusted to the individual risk group. In contrast, for other tumors, such as metastatic bladder carcinoma, recommendations for follow-up do not seem to be individualized. This article therefore gives an overview on current recommendations and evidence for the follow-up of the most important genitourinary tumor types.

Entities:  

Mesh:

Year:  2015        PMID: 26246111     DOI: 10.1007/s00120-015-3936-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  67 in total

1.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

2.  A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Authors:  Scott E Eggener; Alex Mueller; Ryan K Berglund; Raj Ayyathurai; Cindy Soloway; Mark S Soloway; Robert Abouassaly; Eric A Klein; Steven J Jones; Chris Zappavigna; Larry Goldenberg; Peter T Scardino; James A Eastham; Bertrand Guillonneau
Journal:  J Urol       Date:  2013-01       Impact factor: 7.450

3.  Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results.

Authors:  Oguz Akin; David H Gultekin; Hebert Alberto Vargas; Junting Zheng; Chaya Moskowitz; Xin Pei; Dahlia Sperling; Lawrence H Schwartz; Hedvig Hricak; Michael J Zelefsky
Journal:  Eur Radiol       Date:  2011-05-01       Impact factor: 5.315

4.  Patterns and fate of PSA bouncing following 3D-CRT.

Authors:  A L Hanlon; W H Pinover; E M Horwitz; G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

Review 5.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

6.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

7.  Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data.

Authors:  Charlotte Le Cornet; Joannie Lortet-Tieulent; David Forman; Rémi Béranger; Aude Flechon; Béatrice Fervers; Joachim Schüz; Freddie Bray
Journal:  Eur J Cancer       Date:  2013-12-23       Impact factor: 9.162

8.  Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005.

Authors:  Rasmus Hoffmann; Iris Plug; Martin McKee; Bernadette Khoshaba; Ragnar Westerling; Caspar Looman; Gregoire Rey; Eric Jougla; Katrin Lang; Kersti Pärna; Johan P Mackenbach
Journal:  Int J Public Health       Date:  2013-08-29       Impact factor: 3.380

9.  Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Authors:  Monique J Roobol; Ries Kranse; Chris H Bangma; Arno G J L H van Leenders; Bert G Blijenberg; Ron H N van Schaik; Wim J Kirkels; Suzie J Otto; Theo H van der Kwast; Harry J de Koning; Fritz H Schröder
Journal:  Eur Urol       Date:  2013-05-25       Impact factor: 20.096

10.  Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?

Authors:  Tom Pickles; Jeremy Hamm; W James Morris; William E Schreiber; Scott Tyldesley
Journal:  BJU Int       Date:  2012-05-07       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.